Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Mind Medicine (MindMed) Inc MNMD

Alternate Symbol(s):  N.MMED.WA | N.MMED.WR | N.MMED.WS | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Bullboard Posts
Post by josameyeron Dec 07, 2010 4:25pm
531 Views
Post# 17814474

Stanley Re the latest news release

Stanley Re the latest news releaseI was under the impression that we were already drilling in the area outlined in the last release re drilling commencing in Jan 2011. Are we to understand that 2 additional drills will be deployed ?I am somewhat surprised with the new 4 million dollars worth of flowthrough shares. I hoped and thought that the money from the sale to Sandstorm,   was more than adequate.Perhaps these funds do not come into play until next year.Also,  a further response to the alleged lawsuit would be a propos.On the one hand the deficiencies were reported to be  reported, which the other party denies. I am still at a loss .why lately nothing ever is mentioned about notes held in regards to the sale of Montana tunnels., I believe it to be in the  8 million to 9 million dollar range.Also, here are some top institutinal holders in BRD. Sprott 19.81 million. Wellington 19.6 million Craton Cap 5.18 million Baker Steel 3.14 million Rab Cap1.61 million. RBC Asset 1.5 million,Blackrock financial 1.37 million Hillsdale investment 1.18 million and Libra Advisors1.62 million. In addition Mutual Fund holder CF Ruffer Baker Steel 5.6 million Sprott Gold 3.4 million. Blackrock 1.37 million.Then we have the insiders holdings.I still am of the believe  that Brigus Gold has great potential,  especially at the Black Fox, Grey Fox Pike river area. Perhaps it would be better to dispose of the Sakatchewan property. and concentrate solely on the Timmins properties.The foregoing is my opinion only.I believe that we could be on the verge of a major move upward. Lets not take our eye of the ball.Let us be kept informed on all aspects pertaining to the public company BRD.As always DYODD. Cheers Josa.
Bullboard Posts

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse